USFDA inspection concludes with three observations at a formulations plant
The inspection closed with Form 483 observations, none flagged as data integrity issues per the company's filing.
Materiality
28/100
Weighted, auditable score
Companies exposed
1
Direct and second-order
Sources
1
Primary: Company exchange filing
Thesis effect
No material change
Compliance record remains an ongoing monitoring item rather than a thesis change.
Why it matters
The standard format applied to every material event
- What happened
- The inspection closed with Form 483 observations, none flagged as data integrity issues per the company's filing.
- Why it matters
- Observations require a remediation response. Materiality 28/100 on revenue, profit, breadth, persistence, strategic importance and surprise.
- Who is affected
- Sun Pharmaceutical (negative, medium exposure)
- How
- Observations require a remediation response → Remediation adds compliance cost → Escalation risk to a warning letter would affect supply
- Time horizon
- Short term · Temporary
- What to monitor
- Company response filing · Any escalation to warning letter or import alert · Site revenue contribution disclosure
Materiality components
The score is never shown without its inputs
- Revenue exposure22/100
Weight 25% of the materiality score
- Profit exposure25/100
Weight 20% of the materiality score
- Breadth of effect15/100
Weight 15% of the materiality score
- Persistence30/100
Weight 15% of the materiality score
- Strategic importance45/100
Weight 15% of the materiality score
- Surprise vs expectation40/100
Weight 10% of the materiality score
Economic mechanism
Causal chain, not certainty — each step carries the variable it moves
- 1
Observations require a remediation response
Regulation Response window is typically 15 working days
- 2
Remediation adds compliance cost
Cost Usually modest unless escalated
- 3
Escalation risk to a warning letter would affect supply
Supply This is the tail risk, not the base case
Counter-effect
Procedural observations without data integrity findings historically close without supply disruption.
Company impact
Exposure-weighted, never sector membership alone
| Company | Order | Exposure | Impact | Score | Confidence | Reason |
|---|---|---|---|---|---|---|
| SUNPHARMA | Direct | Medium | Negative | 36 | 58% | Site-level compliance risk; scale of the site determines impact |
Impact score components — Sun Pharmaceutical
- Exposure60/100
Weight 25% of the impact score
- Materiality28/100
Weight 20% of the impact score
- Persistence20/100
Weight 15% of the impact score
- Revenue sensitivity12/100
Weight 10% of the impact score
- Margin sensitivity18/100
Weight 10% of the impact score
- Strategic importance45/100
Weight 10% of the impact score
- Surprise40/100
Weight 5% of the impact score
- Confidence58/100
Weight 5% of the impact score
Market reaction
Reaction is evidence about expectations, not confirmation of impact
| Symbol | Day 0 | 1D | 5D | Rel. volume | Read |
|---|---|---|---|---|---|
| SUNPHARMA | -1.2% | 0.4% | 0.8% | 1.3x | Limited reaction, consistent with observations rather than a warning letter |
Fact / calculation / inference / unknown
Inference is never presented as fact
- · Three Form 483 observations
- · No data integrity observations per the company
None recorded.
- · Base case is closure without supply impact
- · Site revenue share
- · Regulator's final classification
Sources
1 report clustered into one event — primary sources ranked first
- PrimaryexchangeCompany exchange filing19 Aug, 08:00 pm
Sun Pharma reports conclusion of USFDA inspection with three observations
The inspection at a formulations facility concluded with Form 483 observations, none related to data integrity.
Ref: NSE/CM/2026-08-19/SUNPHARMA
Event timeline & versions
History is appended, never silently rewritten
- 19 Aug, 08:00 pmConfirmed
Company filing to the exchange.
Source: sample market data · Calculated metrics, not exchange feeds · Algorithm version phase5-impact-1.0.0 · Generated 31/8/2026, 2:57:28 pm. Educational analysis only — not investment advice, and no recommendation to buy or sell any security.
Phase 5 runs on an illustrative event corpus with full source metadata, not a licensed live news feed. Materiality, exposure and impact are computed by versioned rule engines (materiality v1.0.0, impact v1.0.0); confidence and unknowns are shown alongside every conclusion. Nothing here is investment advice.